Open AccessPleiotropic effects of ursodeoxycholic acid in patients with non-alcoholic steatohepatitis with impaired glycemic control
Author(s) -
А. А. Шиповская,
И. В. Курбатова,
О П Дуданова
Publication year - 2020
Publication title -
èksperimentalʹnaâ i kliničeskaâ gastroènterologiâ
Language(s) - English
Resource type - Journals
ISSN - 1682-8658
DOI - 10.31146/1682-8658-ecg-183-11-34-38
Subject(s) - medicine , ursodeoxycholic acid , steatohepatitis , glycemic , prediabetes , insulin resistance , insulin , gastroenterology , endocrinology , diabetes mellitus , type 2 diabetes , fatty liver , disease
The goal was to determine the eect of ursodeoxycholic acid (UDCA) in non-alcoholic steatohepatitis (NASH) with impaired glycemic control. Materials and methods . 67 patients NASH were examined: prediabetes — 38 (56.7%), type 2 diabetes mellitus 29 (43.3%), men — 39 (58.2%), women — 28 (41.8%), age — 45.1 ± 10.2 years. The UDCA dose was 9.4 ± 2.0 mg / kg / day during 59.7 ± 77.6 weeks. Fragments of cytokeratin-18 (FCK-18) (TPS ELISA, Biotech, Sweden), TNF-α (Human TNFα Platinum ELISA, eBioscience, Austria), IL-6 (“Interleukin-6-IFA-Best”, Vector-Best, Russia), insulin (“Insulin TEST System”, Monobind Inc., USA), HOMA-IR were determined. Results . There was a decrease in the levels of FCK-18 — from 238.1 ± 93.7 to 170.7 ± 79.2 U / l (p <0.05), ALT — 61.3 ± 19.0 to 38.9 ± 19.1 U / l (p <0.05), glucose 5.9 ± 1.3 to 5.5 ± 0.7 mmol / l (p <0.05), insulin 21.9 ± 18.2 to 13.7 ± 9.7 MkU / l, HOMA-IR — 5.8 ± 2.2 to 3.1 ± 0.8 (p <0.05), cholesterol — 6.2 ± 0.9 to 5.3 ± 0.3 mmol / l, LDL — 3.9 ± 0.9 to 3.2 ± 0.6 mmol / l (p <0.05), TNF-α 6.3 ± 1.5 to 5.4 ± 2.1 pg / ml (p <0.05), IL-6–7.1 ± 3.4 to 4, 1 ± 3.2 pg / ml (p <0.05). Conclusion . UDCA had pleiotropic eects in NASH with impaired glycemic control, reducing cellular apoptosis, necrosis, inammation, improving insulin sensitivity and lipid homeostasis.